Development of highly potent neutralising nanobodies against multiple SARS-CoV-2 variants including the variant of concern B.1.351
A. M. Sziemel, S.-H. Hwa, A. Sigal, G. Tyson, N. Logan, B. J. Willett, P. J. Durcan
This paper develops potent neutralizing nanobodies against SARS-CoV-2 variants, including B.1.351, to address reduced vaccine efficacy.
bioRxiv · Apr 11, 2021 · PreprintImmunology